TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04575792

Intervention type: BEHAVIORAL
Intervention: Practicing oral habits
Description: children who practice one or more of the specified oral habits ( mouth breathing, object sucking, or tongue thrusting) are considered exposed.
Study: NCT05353140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The WATCHMAN/WATCHMAN FLX device
Description: Watchman device was an umbrella-shaped, self-expanding, nitinol structure with a porous partial polyethylene terephthalate membrane (160 um mesh) and 10 struts. The membrane portion of the structure faces into the body of the left atrial to block embolization of thrombus and provide scaffolding on which endothelialization can occur. The On July 21st, 2020, the FDA approved the next generation LAAO device, named Watchman FLX. This newiteration of the Watchman LAAO platform offers full capability of recapture and redeployment of the device, decreasedmetallic exposure, an increased number of contact points for sealing, a fully rounded delivery shape, and precision anchors designed to provide optimal device engagement with the LAA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban + Clopidogre
Description: Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Clopidogre
Description: Previous pivotal trials have shown that in patients with atrial fibrillation and requiring antiplatelet treatment, a NOAC plus clopidogrel regimen was associated with a lower incidence of bleeding events as compared with a warfarin-based triple antithrombotic strategy. Therefore, the current expert opinions and consensus of North American Societies recommend a NOAC plus a P2Y12 inhibitor in patients with AF and PCI. In the present study, Rivaroxaban + Clopidogre are required for 45 days in LAAO group after LAAO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel
Description: Aspirin + Clopidogrel are required from 46 days to 12 months after LAAO.
Study: NCT05612412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morning Exercise
Description: Standardized treadmill exercise session starting at approximately 0700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening Exercise
Description: Standardized treadmill exercise session starting at approximately 1800
Study: NCT05330078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.
Study: NCT05763355

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: Biopsies will be performed under local anaesthesia. In all patients with a suspicious lesion (PIRADSv2.1 3-5) noted on the mp-MRI, the software-based image fusion biopsies will be obtained collecting 3 to 5 cores per target area according to its volume, 10-12 systematic cores of the remaining areas of the prostate will be collected from sectors specified in the PIRADSv2.1 prostate map.
Study: NCT06115902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Study: NCT05754138

Intervention type: DEVICE
Intervention: Sport SICD
Description: Follow up
Study: NCT05515718

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain management
Description: Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician, under strict aseptic conditions After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral nerve block
Description: Patients undergo ultrasound-guided femoral nerve blockperformed by a trained emergency physician under strict aseptic conditions, immediately after oral informed consent is obtained. After the femoral nerve block is performed, the patient is monitored and (BP, HR, SpO2, ECG) during 90 minutes.
Study: NCT05043311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection
Study: NCT05970887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
Description: The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
Description: The bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine is a combination of 15-µg of mRNA encoding the wild-type (WT) spike protein and 15-µg of mRNA encoding the spike protein of the Omicron BA.4/BA.5 subvariant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent influenza vaccine
Description: The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: quadrivalent influenza vaccine
Description: The quadrivalent influenza vaccine is an inactivated vaccine containing 15μg HA/strain in each 0.5-mL dose, containing four influenza vaccine strains from the 2022-2023 northern hemisphere season
Study: NCT05215522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BCI-FES Intervention
Description: To evaluate whether the participant can effectively control FES using the developed remote BCI system. Thus, participants will receive a three-week BCI-FES intervention at their home, including three sessions of intervention per week. Each session will last around 60 minutes, including 10 minutes of preparation, 40 minutes of intervention and 10 minutes interview on the user's experience with the device and any experienced side effects, if any.
Study: NCT06112873

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Patient (or Parent)-Reported Outcomes via specific questionnaires

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Patient (or Parent)-Reported Outcomes via specific questionnaires

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Patient (or Parent)-Reported Outcomes via specific questionnaires
Study: NCT06192121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Based Education
Description: In this research, a reminder message will be sent 3 times a week along with web-based training.
Study: NCT06456710

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional IBS Health Education
Description: Patients were provided with IBS related knowledge (e.g., the pathogenesis of IBS and the reasons affecting the treatment effect), exercise guidance, drug guidance and dietary management precautions; and timely answers to patients' clinical problems and psychological support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Based on ACT Theory of Psychological Intervention
Description: On the basis of the control group, the stigma intervention program of college students with IBS based on ACT theory was implemented. The duration of intervention was 40 to 50 minutes for 6 times, once a week for 6 weeks.~Week1: established relationships; introduced the core contents of ACT, the treatment process, and the effects of application.~Week2: encouraged to express negative emotions and behaviors; made patients accept the disease.~Week3: explained the importance of coping with negative emotions; instructed to separate negative thoughts from reality through cognitive dissociation exercises.~Week4: changed the concept of self and actively accepted IBS; guided to focus on the current life and true self.~Week5: introduced the values in ACT; helped clarify the values; guided to build confidence and focused on the core values.~Week6: introduced the importance of commitment to action; developed goals and plans together; encouraged to strengthen the use of ACT.
Study: NCT04783662

Intervention type: DEVICE
Intervention: Intraoperative frontal electroencephalogram
Description: Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane

Intervention type: DEVICE
Intervention: Intraoperative frontal electroencephalogram
Description: Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane

Intervention type: DEVICE
Intervention: Intraoperative frontal electroencephalogram
Description: Intra operative frontal electroencephalogram registration with 1 age adjusted Minimum Anesthetic Concentration of Sevoflurane
Study: NCT06078670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL218
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL218
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL218
Description: Arm1: Triple negative breast cancer CVL218 is administered orally Triplelizumab injection was administered intravenously (IV) 240mg on D1 Paclitaxel injection (Kealil) 125mg /m2, D1, D8 administration Every 21 days for a drug cycle; Arm2: Gastric cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Paclitaxel injection (Taxol) 175mg /m2, D1 administration Every 21 days for a drug cycle; Arm3: Intestinal cancer CVL218 is administered orally Sindilizumab injection was given intravenously (IV) 200mg on D1 Fuquinitinib capsule 5mg QD orally, D1-14 administration Every 21 days is a medication cycle.
Study: NCT04626141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dispensed as a 30-day supply of disposable pen injections.
Study: NCT06181045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT05043311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection
Study: NCT06076278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resistance exercise
Description: Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
Study: NCT04526782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib 75 MG
Description: 450 mg (6 × 75 mg capsule) per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib 75 MG
Description: 450 mg (6 × 75 mg capsule) per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: 45 mg (3 × 15 mg tablet) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib 15 MG
Description: 45 mg (3 × 15 mg tablet) twice daily
Study: NCT05279040

Intervention type: DRUG
Intervention: Trikafta
Description: Elexacaftor/Tezacaftor/Ivacaftor combination therapy
Study: NCT05358405

Intervention type: OTHER
Group type: OTHER
Intervention: Müller maneuver
Description: The Müller maneuver allows maximum inspiratory pressure measurement via a one-way valve connected to the intubation tube and is currently used in routine care for diaphragmatic assessment. Ventilation through the one-way valve results in forced inspiration for about 20 seconds. The endothoracic depression induced by this test is likely increasing venous return and cardiac output in patients with preload reserve, i.e. in preload-dependent patients. The observation of an increase in cardiac output during a Müller maneuver could reflect the existence of a dependent preload state, i.e. with a reserve of preload, and de facto lower risk of pulmonary oedema. This test would be an easy alternative to the passive leg raising test used in current practice to evaluate the preload dependency and the risk of weaning induced pulmonary edema.
Study: NCT05644340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speed 8 (Fast balancing gas flow)
Description: General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 8. The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Speed 4 (Medium speed balancing gas flow)
Description: General anesthesia will be induced via intravenous agents, and anesthesia maintenance will be provided via inhalation for all the patients. The maintenance will be provided with sevoflurane using automated gas flow with the selected speed of 4 (Medium speed). The anesthesia machine indicates amount of sevoflurane inhaled, inspired and exhaled oxygen, carbon dioxyde, air and sevoflurane concentrations. Accordingly these data and actual flow rate will be recorded every 15 minutes.
Study: NCT03982030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Dalbavancin 1.5g IV at day 0, day 8-10
Study: NCT04705714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frankincense Extract
Description: The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
Study: NCT06231745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and sometimes obsessive compulsive disorder (OCD), panic attacks, anxiety or post-traumatic stress disorder (PTSD).
Study: NCT04962594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental formulas (EF)
Description: First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control formulas (CF)
Description: First age formula administered orally ad libitum until 6 months of age, switch to second age formula until 12 months and finally to growing-up milk from 12 to 15 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast feeding (BF)
Description: Exclusive breast feeding up to 4 months
Study: NCT05236634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphodiesterase 5 Inhibitors
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study: NCT05688228

Intervention type: OTHER
Intervention: questionnaire
Description: Female Sexual Function Index (FSFI) and self-administrative questionnaires on sexuality just after abortion and repeated at 1, 3 and 6 months
Study: NCT06076278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resistance exercise
Description: Isometrics contraction of quadriceps Supine straight leg raise Leg lifts in prone position Passive knee flexion Passive knee extension Resistance knee extension Resistance knee flexion Isometric terminal knee extension in lying and mini-squat Concentric and isometric knee extension and flexion in sitting Frequency: A total of 12 sessions, thrice a week, for 4 consecutive weeks. Time Duration: Approx. 25 to 30minutes
Study: NCT05198544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hēlaquis Matrix is a hyaluronic acid matrix (HaM)
Description: Hēlaquis Matrix is a hyaluronic acid matrix (HaM) derived from the American Alligator and indicated for the treatment of chronic wounds. Hyaluronic Acid (HA) is a naturally occurring non sulphated glycosaminoglycan consisting of a linear sequence of D-glucuronic and N -acetyl-Dglucosamine. It is present in connective tissue and plays a role in several biological processes including tissue repair.
Study: NCT05284253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gold microparticles
Description: Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gold thiosulphate
Description: Gold Sodium Thio Sulphate, 1 % w/v in petrolatum
Study: NCT05568004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: aerobic plus resistance exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Only aerobic exercise
Study: NCT04954872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Problem Management Plus training (training as usual)
Description: 10-day training on Problem Management Plus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Equip-based Problem Management Plus training
Description: Training and supervision for Problem Management Plus in which the trainers and supervisors use the EQUIP platform for competency assessment and feedback.
Study: NCT05043311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injetion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injetion